Toleranzia
0,592
SEK
-2,95 %
TOL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Mindre end 1K følgere
-2,95%
-6,92%
-0,34%
+16,54%
+15,18%
+13,85%
-47,61%
-79,2%
-91,02%
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Læs mereMarkedsværdi
160,41 mio. SEK
Aktieomsætning
26,33 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
21.2
2025
Årsrapport '24
6.5
2025
Delårsrapport Q1'25
5.6
2025
Generalforsamling '25
ViserAlle indholdstyper
Toleranzia AB provides update on clinical trial application
Toleranzia AB appoints SKMG as new Certified Adviser
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools